01.05.2019 • News

Axens Wins Petchems Contracts

Axens Wins Petchems Contracts (c) mmmx/Shutterstock
Axens Wins Petchems Contracts (c) mmmx/Shutterstock

French technology provider Axens has won contracts in China and India to supply several of its proprietary process units.

The most recent contract was awarded by China’s Shenghong Refining & Chemical (Lianyungang) Co., which has chosen Axens’ H-Oil and HyK hydrocracking processes for its petrochemical complex in Lianyungang, Jiangsu. The two single-train units will increase naphtha capacity by 3.6 million t/y.

Axens said the residue hydrocracking units will allow Shenghong to further improve its economic resilience and competitiveness. Jacques Rault, director of Axens’ middle distillates & conversion business line, said the routing optimization between the distillate hydrocracking HyK unit and the H-Oil unit delivers superior naphtha yields.

In early April, Axens announced it had been selected by HPCL Rajasthan Refinery (HRRL), a joint venture between Hindustan Petroleum Co. Ltd. (HPCL) and the government of Rajasthan in India, to supply several of its technologies for a 9 million t/y integrated refinery and petrochemical complex to be established in Pachpadra Tehsil of Barmer district, Rajasthan.

Axens will provide a naphtha hydrotreater, a C5-C6 isomerization unit, and an AlphaButol high-purity 1-butene unit, among several other facilities. “With these numerous technologies, HRRL will be well positioned to supply the market with cleaner fuels and also high-quality petrochemicals for the coming decades,” commented Axens chairman and CEO, Jean Sentenac.

A timescale and completion dates for both projects have not been disclosed.

 

######

www.axens.net

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.